摘要
目的观察XELOX化疗方案用于老年晚期胃癌患者治疗的近期临床疗效和不良反应。方法将45例老年晚期胃癌患者按采用的化疗方案分为A组(n=22)及B组(n=23),A组患者采用XELOX方案全身化疗,每21天为1个周期,共2个周期;B组患者采用FOLFOX4方案全身化疗,每2周为1个周期,共4个周期。评价两组患者的近期疗效及不良反应。结果 A、B组患者治疗有效率分别为54.5%、26.1%,生活质量改善有效率分别为72.7%、47.8%,两组比较,差异均有统计学意义(P<0.05)。两组患者的主要不良反应为胃肠道反应、骨髓抑制、周围神经毒性及手足综合征,A组患者的不良反应发生率明显低于B组(P<0.05)。A、B组患者的中位疾病进展时间分别为5.3、4.2个月,中位生存期分别为9.6、8.3个月。结论 XELOX方案治疗老年晚期胃癌疗效较好,不良反应较低,可改善患者的生活质量。
Abstract：Objective To observe short-term clinical efficacy and adverse reactions of XELOX chemotherapeutic scheme in treatment of elderly patients with advanced gastric cancer. Methods 45 elderly patients with advanced gastric cancer were divided into group A（n=22） and group B（n= 23） according to chemotherapeutic schemes. Patients in group A accepted systemic XELOX chemotherapeutic scheme of 2 circles,with 21 days in each circle,and patients in group B were subjected to systemic FOLFOX4 chemotherapeutic scheme of 4 circles, with each circle including 2 weeks. Short-term efficacy and adverse reactions of patients in the two groups were evaluated. Results Effective ratios of treatment and life quality improvement of patients in group A and B were 54.5%,26. 1% and 72. 7%, 47. 8% ,respectively, with statistically significant differences when compared the two groups （P〈 0.05）. The major adverse reactions of patients in two groups were gastrointestinal reactions, bone marrow suppression, peripheral neurotoxicity and hand-foot syndrome. Incidence rate of adverse reaction of patients in group A was markedly lower than that in group B（P〈0.05）. Median durations of disease progression of patients in group A and B were 5.3 and 4.2 months, respectively, and median survival durations were 9.6 and 8.3 months, respectively. Conclusion XELOX scheme,which has relatively good curative effects and less adverse reaction in treatment of elderly patients with advanced gastric cancer,can improve their life quality.
出处
《重庆医学》
CAS
CSCD
北大核心
2013年第2期156-159,共4页
Chongqing medicine
关键词
胃肿瘤
抗肿瘤联合化疗方案
治疗结果
奥沙利铂
卡培他滨
stomach neoplasms
antineoplastic combined chemotherapy protocols
treatment outcome
oxaliplatin
capecitabine
